Chandra Datta Sumi1, Aaron J Heffernan1,2, Jeffrey Lipman3, Jason A Roberts4,5,6,7, Fekade B Sime1. 1. Centre for Translational Anti-Infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia. 2. School of Medicine, Griffith University, Gold Coast, QLD, Australia. 3. Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. 4. Centre for Translational Anti-Infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, QLD, Australia. j.roberts2@uq.edu.au. 5. The University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. j.roberts2@uq.edu.au. 6. Department of Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. j.roberts2@uq.edu.au. 7. Pharmacy Department, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia. j.roberts2@uq.edu.au.
Abstract
BACKGROUND: The rates of antibiotic resistance in Gram-negative bacteria are increasing. One method to minimize resistance emergence may be optimization of antibiotic dosing regimens to achieve drug exposure that suppress the emergence of resistance. OBJECTIVE: The aim of this systematic review was to describe the antibiotic exposures associated with suppression of the emergence of resistance for Gram-negative bacteria. METHODS: We conducted a search of four electronic databases. Articles were included if the antibiotic exposure required to suppress the emergence of resistance in a Gram-negative bacterial isolate was described. Among studies, 57 preclinical studies (in vitro and in vivo) and 2 clinical studies 59 included investigated the monotherapy of antibiotics against susceptible and/or intermediate Gram-negative bacteria. RESULTS: The pharmacokinetic/pharmacodynamic (PK/PD) indices reported to suppress the emergence of antibiotic resistance for various classes were β-lactam antibiotic minimum concentration to minimum inhibitory concentration (Cmin/MIC) ≥ 4; aminoglycoside maximum concentration to MIC (Cmax/MIC) ratio ≥ 20; fluoroquinolones, area under the concentration-time curve from 0 to 24 h to mutant prevention concentration (AUC24/MPC) ≥ 35; tetracyclines, AUC24 to MIC (AUC24/MIC) ratio ≥ 50; polymyxin B, AUC24/MIC ≥ 808; and fosfomycin, AUC24/MIC ≥ 3136. However, the exposures required to suppress the emergence of resistance varied depending on the specific antibiotic tested, the duration of the experiment, the bacterial species and the specific bacterial isolate tested. Importantly, antibiotic exposures required to suppress the emergence of resistance generally exceeded that associated with clinical efficacy. CONCLUSION: The benefits of implementing such high PK/PD targets must be balanced with the potential risks of antibiotic-associated toxicity.
BACKGROUND: The rates of antibiotic resistance in Gram-negative bacteria are increasing. One method to minimize resistance emergence may be optimization of antibiotic dosing regimens to achieve drug exposure that suppress the emergence of resistance. OBJECTIVE: The aim of this systematic review was to describe the antibiotic exposures associated with suppression of the emergence of resistance for Gram-negative bacteria. METHODS: We conducted a search of four electronic databases. Articles were included if the antibiotic exposure required to suppress the emergence of resistance in a Gram-negative bacterial isolate was described. Among studies, 57 preclinical studies (in vitro and in vivo) and 2 clinical studies 59 included investigated the monotherapy of antibiotics against susceptible and/or intermediate Gram-negative bacteria. RESULTS: The pharmacokinetic/pharmacodynamic (PK/PD) indices reported to suppress the emergence of antibiotic resistance for various classes were β-lactam antibiotic minimum concentration to minimum inhibitory concentration (Cmin/MIC) ≥ 4; aminoglycoside maximum concentration to MIC (Cmax/MIC) ratio ≥ 20; fluoroquinolones, area under the concentration-time curve from 0 to 24 h to mutant prevention concentration (AUC24/MPC) ≥ 35; tetracyclines, AUC24 to MIC (AUC24/MIC) ratio ≥ 50; polymyxin B, AUC24/MIC ≥ 808; and fosfomycin, AUC24/MIC ≥ 3136. However, the exposures required to suppress the emergence of resistance varied depending on the specific antibiotic tested, the duration of the experiment, the bacterial species and the specific bacterial isolate tested. Importantly, antibiotic exposures required to suppress the emergence of resistance generally exceeded that associated with clinical efficacy. CONCLUSION: The benefits of implementing such high PK/PD targets must be balanced with the potential risks of antibiotic-associated toxicity.
Authors: Brian Vanscoy; Rodrigo E Mendes; Mariana Castanheira; Jennifer McCauley; Sujata M Bhavnani; Alan Forrest; Ronald N Jones; Olanrewaju O Okusanya; Lawrence V Friedrich; Judith Steenbergen; Paul G Ambrose Journal: Antimicrob Agents Chemother Date: 2013-06-17 Impact factor: 5.191
Authors: Vincent H Tam; Kai-Tai Chang; Jian Zhou; Kimberly R Ledesma; Kady Phe; Song Gao; Françoise Van Bambeke; Ana María Sánchez-Díaz; Laura Zamorano; Antonio Oliver; Rafael Cantón Journal: J Antimicrob Chemother Date: 2017-05-01 Impact factor: 5.790
Authors: Andrea Bacconi; Gregory S Richmond; Michelle A Baroldi; Thomas G Laffler; Lawrence B Blyn; Heather E Carolan; Mark R Frinder; Donna M Toleno; David Metzgar; Jose R Gutierrez; Christian Massire; Megan Rounds; Natalie J Kennel; Richard E Rothman; Stephen Peterson; Karen C Carroll; Teresa Wakefield; David J Ecker; Rangarajan Sampath Journal: J Clin Microbiol Date: 2014-06-20 Impact factor: 5.948
Authors: Iain J Abbott; Joseph Meletiadis; Imane Belghanch; Rixt A Wijma; Lamprini Kanioura; Jason A Roberts; Anton Y Peleg; Johan W Mouton Journal: J Antimicrob Chemother Date: 2018-03-01 Impact factor: 5.790
Authors: Roger L Nation; Samira M Garonzik; Visanu Thamlikitkul; Evangelos J Giamarellos-Bourboulis; Alan Forrest; David L Paterson; Jian Li; Fernanda P Silveira Journal: Clin Infect Dis Date: 2016-12-23 Impact factor: 9.079
Authors: Mahipal G Sinnollareddy; Michael S Roberts; Jeffrey Lipman; Sandra L Peake; Jason A Roberts Journal: J Antimicrob Chemother Date: 2018-06-01 Impact factor: 5.790
Authors: Isabelle K Delattre; Fabio S Taccone; Frédérique Jacobs; Maya Hites; Thierry Dugernier; Herbert Spapen; Pierre-François Laterre; Pierre E Wallemacq; Françoise Van Bambeke; Paul M Tulkens Journal: Expert Rev Anti Infect Ther Date: 2017-06-19 Impact factor: 5.091
Authors: Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner; Alexander A Firsov Journal: Antimicrob Agents Chemother Date: 2015-12-07 Impact factor: 5.191
Authors: Timothy M Rawson; Richard C Wilson; Danny O'Hare; Pau Herrero; Andrew Kambugu; Mohammed Lamorde; Matthew Ellington; Pantelis Georgiou; Anthony Cass; William W Hope; Alison H Holmes Journal: Nat Rev Microbiol Date: 2021-06-22 Impact factor: 60.633
Authors: Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts Journal: Intensive Care Med Date: 2020-05-07 Impact factor: 17.440
Authors: Pier Giorgio Cojutti; Davide Lazzarotto; Anna Candoni; Maria Vittoria Dubbini; Maria Elena Zannier; Renato Fanin; Federico Pea Journal: J Antimicrob Chemother Date: 2020-10-01 Impact factor: 5.790
Authors: M Edlinger-Stanger; V Al Jalali; M Andreas; W Jäger; M Böhmdorfer; M Zeitlinger; D Hutschala Journal: Antimicrob Agents Chemother Date: 2021-07-19 Impact factor: 5.191
Authors: Alessandra Oliva; Ambrogio Curtolo; Lorenzo Volpicelli; Francesco Cogliati Dezza; Massimiliano De Angelis; Sara Cairoli; Donatella Dell'Utri; Bianca Maria Goffredo; Giammarco Raponi; Mario Venditti Journal: Antibiotics (Basel) Date: 2021-06-27